TOTAL: $57.375M | ||||
Year to Date: $467.05M | ||||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
Ablynx* (Belgium) |
Procter & Gamble Co. |
ND |
Milestone payment |
Ablynx received payment for the discovery of Nanobodies against a second target for possible new treatments in the musculoskeletal area (6/18) |
Albany Molecular Research Inc. (AMRI) |
Bristol-Myers Squibb Co. |
$1.5 |
Milestone payment |
Albany molecular received the payment for proceeding into preclinical development with a compound to treat depression and diseases of the central nervous system (6/11) |
A.P. Pharma Inc.* |
Paul Royalty Fund affiliate |
$2.5 |
Milestone payment |
The payment is in connection to the company's October agreement to sell its royalty rights to dermatology products Regin-A Micro and Carac (6/7) |
Applied Genetic Technologies Corp.* |
Genzyme Corp. (GENZ) |
$2 |
Milestone payment |
Applied Genetic received the payment for its successful transfer of its adeno-associated virus vector production technology (6/21) |
Bacilligen Inc.* |
Maryland Department of Business and Economic Development |
$0.05 |
Investment |
Bacilligen received a $50,000 investment from Maryland's Challenge Investment Program fund to advance the company's three technology platforms (6/26) |
Eurand NV (Italy; EURX) |
GlaxoSmithKline plc (UK) |
$1 |
Milestone payment |
Eurand received $1M from GSK, which started a registration bioequivalence study for a new orally disintegrating tablet formulation of an undisclosed compound (6/5) |
Genmab A/S (Denmark; CSE:GEN) |
GlaxoSmithKline plc (UK) |
DKK116.3 |
Milestone payment |
Genmab received the payment for reporting positive efficacy results in a Phase II study in rheumatoid arthritis (6/26) |
Immunotope Inc.* |
Ben Franklin Technology Partners of Southeastern PA |
$0.35 |
Investment |
Immunotrope received the money to fund its Phase I IMT-1012 immunotherapeutic vaccine trial (6/26) |
Noven Pharmaceuticals Inc. (NOVN) |
Shire plc (UK) |
$5.9 |
Milestone payment |
Noven received a $5.9M payment after Shire exercised an option to acquire exclusive development rights to a new transdermal patch for ADHD to be formulated by Noven (6/20) |
Pharmacopeia Drug Discovery Inc. (PCOP) |
GlaxoSmithKline plc (UK) |
$5 |
Milestone payment |
Pharmacopeia received the payment in connection with a March 2006 collaboration; it was triggered by Pharmacopeia's completion of certain early discovery activities (6/13) |
Proteros Biostructures GmbH* (Germany) |
Bayer HealthCare AG (Germany) |
ND |
Milestone payment |
Proteros is due a payment for the progress in its collaboration with Bayer in the field of fragment-based protein crystallography (6/20) |
Renovis Inc. (RNVS) |
Pfizer Inc. |
$4.5 |
Milestone payments |
Renovis received the payments as part of its research collaboration with Pfizer to develop vanilloid receptor 1 antagonists for treating pain and other conditions (6/8) |
Sunesis Pharmaceuticals Inc. (SNSS) |
SARcode Corp. |
$0.375 |
Milestone payment |
Sunesis earned a $375,000 convertible note from SARcode for the latter's selection of an LFA-1 inhibitor development candidate and the commencement of GLP toxicology studies (6/5) |
Transgene SA (France; FSE:TGNA) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
€10 |
Milestone payment |
Transgene received the payment for the U.S. and European regulatory authorities' reviews of Phase III plans for TG 4001/R3484 (MVA-HPV-IL-2) in high-grade cervical intraepithelial neoplasia (6/1) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. FSE = Frankfurt Stock Exchange. |